Table 3.
VA outcomes.
| IVD | No IVD | P value | |
|---|---|---|---|
| 71/84 (84%) | 13/84 (16%) | ||
| VA, pre-endophthalmitis | n = 67 | n = 13 | |
| Mean | 20/90 | 20/70 | 0.57 |
| Range | 20/20-LP | 20/25–20/400 | |
| VA, presentation | n = 70 | n = 13 | |
| Mean | 0.9/200 | 1.7/200 | 0.23 |
| Range | 20/40-NLP | 20/80-LP | |
| VA, 1 month | n = 66 | n = 12 | |
| Mean | 5/200 | 1.8/200 | 0.14 |
| Range | 20/25-NLP | 20/25-NLP | |
| ≥3 lines Improvement | 44 (67%) | 3 (25%) | 0.01 |
| logMARΔ | 0.85 | 1.56 | 0.02 |
| VA, 3 months | n = 56 | n = 9 | |
| Mean | 7/200 | 3/200 | 0.36 |
| Range | 20/25-NLP | 20/25-LP | |
| ≥3 lines Improvement | 36 (64%) | 3 (33%) | 0.14 |
| logMARΔ | 0.74 | 1.33 | 0.14 |